Dirk Skowasch

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19

Joana P. Bernardes, Neha Mishra, Florian Tran et al. · Immunity · 2020 · 400 citations · Full text

Erythroid Cells, Long Covid, Immunology +4

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension

Marius M. Hoeper, Christine Pausch, Karen M. Olsson et al. · European Respiratory Journal · 2021 · 309 citations · Full text

Strategy for Safe Performance of Extrathoracic Magnetic Resonance Imaging at 1.5 Tesla in the Presence of Cardiac Pacemakers in Non–Pacemaker-Dependent Patients

Torsten Sommer, Claas P. Naehle, Alexander Yang et al. · Circulation · 2006 · 258 citations

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

Jürgen Behr, Michael Kreuter, Marius M. Hoeper et al. · European Respiratory Journal · 2015 · 230 citations · Full text